TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00473174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Dosing on awakening versus bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Dosing on awakening versus bedtime

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
Study: NCT01783977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1 vaccine
Description: NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1 vaccine
Description: NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1 vaccine
Description: NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid
Study: NCT00498212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1018 ISS-HBsAg-Single
Description: Intramuscular (IM) injection at Day 0, Week 4 and Week 24

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1018 ISS-HBsAg-Double
Description: Intramuscular (IM) injection at Day 0, Week 4 and Week 24
Study: NCT01350076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional liberal fluid regimen
Description: Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restricted fluid regimen
Description: Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index
Study: NCT02635295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile cooperation during the clinical practicum
Description: The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT.
Study: NCT04417985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT, MRI
Study: NCT03145220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EA-230
Description: Active intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl)
Description: Placebo intervention
Study: NCT01483560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 3 years treatment duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 years duration
Study: NCT01734902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Description: sugar coated tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Description: drops for oral administration
Study: NCT02395276

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body hypothermia
Description: Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
Study: NCT01783977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4 vaccine
Description: NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid
Study: NCT02395276

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Whole body hypothermia
Description: Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
Study: NCT02578901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
Study: NCT04426474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT02027792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cabbage leave wraps

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Gel
Study: NCT00397540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEIT
Description: Percutaneous Ethanol Injection Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFTA
Description: Radiofrequency Thermal Ablation
Study: NCT03290027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-03
Description: DFD-03 Lotion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Vehicle (tazarotene 0%) Lotion
Study: NCT01783977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4 vaccine
Description: NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4 vaccine
Description: NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA-HIV-PT123 vaccine
Description: Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA-HIV-PT123 vaccine
Description: Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA-HIV-PT123 vaccine
Description: Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NYVAC-HIV-PT1 vaccine
Description: Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NYVAC-HIV-PT1 vaccine
Description: Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NYVAC-HIV-PT1 vaccine
Description: Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NYVAC-HIV-PT4 vaccine
Description: Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NYVAC-HIV-PT4 vaccine
Description: Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NYVAC-HIV-PT4 vaccine
Description: Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
Study: NCT01482013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP854
Description: Oral, once a day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once a day for 28 days.
Study: NCT01640821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CdM? program
Description: The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
Study: NCT05633368

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~* Patient Health Questionnaire (PHQ-9)~* Clinical Global Impression (CGI)~* Scaling question regarding depressive symptomatology

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~* Patient Health Questionnaire (PHQ-9)~* Clinical Global Impression (CGI)~* Scaling question regarding depressive symptomatology
Study: NCT01444235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N
Description: Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol
Description: Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
Study: NCT01777893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High protein/ high intensity physical activity (HP-HI)
Description: Participants follow a high protein diet and a high intensity physical activity intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High protein / moderate intensity physical activity (HP-MI)
Description: Participants follow a high protein diet and moderate intensity physical activity intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate protein/ high intensity physical activity (MP-HI)
Description: Participants follow a moderate protein diet and a high intensity physical activity intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate protein/ moderate intensity physical activity (MP-MI)
Description: Participants follow a moderate protein diet and moderate intensity physical activity intervention
Study: NCT02993510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondro-Gide sutured
Description: Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondro-Gide glued
Description: Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
Study: NCT01425983

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: amino acid composition (asn01)
Description: Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks
Study: NCT02305901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: single dose on day 1 of visits 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004 tablet
Description: multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion extended release tablet
Description: single dose on day 3 of visits 2 and 3
Study: NCT00458406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-Flex
Description: Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months.
Study: NCT02837692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 10 milligram (mg)
Description: JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 20 mg
Description: JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 40 mg
Description: JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 60 or 80 mg
Description: JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
Study: NCT02164513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate (FF)
Description: FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate (FF)
Description: FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilanterol (VI)
Description: VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilanterol (VI)
Description: VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilanterol (VI)
Description: VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
Study: NCT02169479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25
Description: Immediate-release levodopa/carbidopa 100/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25
Description: Immediate-release levodopa/carbidopa 100/25 mg
Study: NCT02164513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umeclidinium bromide (UMEC)
Description: UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umeclidinium bromide (UMEC)
Description: UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
Study: NCT00798694

Intervention type: DRUG
Group type: OTHER
Intervention: Xalatan
Description: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Xalatan
Description: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Travatan Z
Description: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime

Intervention type: DRUG
Group type: OTHER
Intervention: Travatan Z
Description: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
Study: NCT02027116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-6150
Description: Plasmid DNA delivered via IM injection with electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-6150
Description: Plasmid DNA delivered via IM injection with electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-6150
Description: Plasmid DNA delivered via IM injection with electroporation
Study: NCT02558153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB, drug eluting balloon
Description: Percutaneous angioplasty performed with a DEB - drug eluting balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard PTA
Description: Percutaneous angioplasty performed with a standard balloon
Study: NCT04178681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% vegetable blend
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% vegetable blend
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% vegetable blend
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% vegetable blend
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% vegetable blend
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% vegetable blend
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% AMF
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% AMF
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% AMF
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
Study: NCT00668707

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 20 mgs ingested nightly

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: similar to experimental in all ways except for lack of active ingredient
Study: NCT04178681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% AMF
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% AMF
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% AMF
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% cream
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% cream
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% cream
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% cream
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
Study: NCT04575714

Intervention type: OTHER
Intervention: Data record
Description: Data record
Study: NCT00493454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: .3 mCi IV Over 10 Minutes x 1 Day
Study: NCT04178681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% cream
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% cream
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
Study: NCT03596359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education with Teach-Back method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Received routine treatment